New kind of flu shot is on the way as the FDA approves Moderna’s mRNA-based vaccine
Aug 6, 2026, 12:26 PM
FILE - The Food and Drug Administration seal is seen at the Hubert Humphrey Building Auditorium in Washington, April 22, 2025. The agency has approved a new flu vaccine for older people which is made with the same mRNA technology that was key to ending the COVID-19 pandemic. (Jose Luis Magana, Associated Press)
(Jose Luis Magana, Associated Press)
WASHINGTON (AP) — The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, manufacturer Moderna said.
The shot, named mFlusiva, is intended for adults age 50 or older. Other brands of flu shots already have begun arriving in pharmacies ahead of fall vaccination season, and Moderna said late Wednesday that it expects some of its new version to be available soon at select retailers.
Utah news: Utah doctors urge extra MMR vaccine for infants after recent measles outbreak
While there already are multiple flu vaccine options in the U.S., including three specifically recommended for people age 65 or older, tens of thousands of Americans die from influenza every year and older adults are among the most vulnerable.
Flu vaccines must be updated annually to best match circulating strains of the virus. Vaccines made with the Nobel Prize-winning mRNA technology are faster to manufacturer than other types, and experts say this additional option might help if the shape-shifting flu virus mutates in a way that requires suddenly brewing new doses.
Moderna said the FDA granted full approval for mFlusiva’s use in people ages 50 to 64, based on a study of 40,000 people that found 27% fewer flu cases among people who got the new shot compared with those who got a different common flu vaccine brand. For people 65 or older, the Cambridge, Massachusetts-based manufacturer said the FDA granted what’s called accelerated approval for the shot — based on a smaller study showing it generated a strong immune response compared with an existing high-dose vaccine for seniors – while it conducts an additional study.
Moderna’s data showed no major safety issues although the shot did cause some temporary reactions including injection site pain, fever, headache, tiredness and aches that occurred somewhat more than with today’s flu shots.
The FDA action comes after a highly unusual public dispute over mFlusiva earlier this year. A then-top FDA official blocked the company’s application, a sign of the agency’s heightened vaccine scrutiny under Health Secretary Robert F. Kennedy Jr. Days later, the agency changed course after Moderna publicly challenged the ruling — and in June a panel of independent advisers to the FDA unanimously recommended the vaccine’s approval.
___
Follow the AP’s coverage of the U.S. Food and Drug Administration at https://apnews.com/hub/us-food-and-drug-administration.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
